| Donepezil and memantine for moderate-to-severe Alzheimer's disease R Howard, R McShane, J Lindesay, C Ritchie, A Baldwin, R Barber, ... New England Journal of Medicine 366 (10), 893-903, 2012 | 972 | 2012 |
| Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis SH Gillespie, AM Crook, TD McHugh, CM Mendel, SK Meredith, ... New England Journal of Medicine 371 (17), 1577-1587, 2014 | 742 | 2014 |
| High-dose rifapentine with moxifloxacin for pulmonary tuberculosis A Jindani, TS Harrison, AJ Nunn, PPJ Phillips, GJ Churchyard, ... New England Journal of Medicine 371 (17), 1599-1608, 2014 | 517 | 2014 |
| Four-month rifapentine regimens with or without moxifloxacin for tuberculosis SE Dorman, P Nahid, EV Kurbatova, PPJ Phillips, K Bryant, KE Dooley, ... New England Journal of Medicine 384 (18), 1705-1718, 2021 | 446 | 2021 |
| A trial of a shorter regimen for rifampin-resistant tuberculosis AJ Nunn, PPJ Phillips, SK Meredith, CY Chiang, F Conradie, D Dalai, ... New England Journal of Medicine 380 (13), 1201-1213, 2019 | 419 | 2019 |
| High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial MJ Boeree, N Heinrich, R Aarnoutse, AH Diacon, R Dawson, S Rehal, ... The Lancet infectious diseases 17 (1), 39-49, 2017 | 414 | 2017 |
| A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis MJ Boeree, AH Diacon, R Dawson, K Narunsky, J Du Bois, A Venter, ... American journal of respiratory and critical care medicine 191 (9), 1058-1065, 2015 | 378 | 2015 |
| A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis MZ Imperial, P Nahid, PPJ Phillips, GR Davies, K Fielding, D Hanna, ... Nature medicine 24 (11), 1708-1715, 2018 | 317 | 2018 |
| Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment SO Friedrich, A Rachow, E Saathoff, K Singh, CD Mangu, R Dawson, ... The lancet Respiratory medicine 1 (6), 462-470, 2013 | 222 | 2013 |
| Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses R Howard, R McShane, J Lindesay, C Ritchie, A Baldwin, R Barber, ... The Lancet Neurology 14 (12), 1171-1181, 2015 | 209 | 2015 |
| Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized … AJ Nunn, ID Rusen, A Van Deun, G Torrea, PPJ Phillips, CY Chiang, ... Trials 15, 1-10, 2014 | 179 | 2014 |
| Determining the minimum clinically important differences for outcomes in the DOMINO trial R Howard, P Phillips, T Johnson, J O'Brien, B Sheehan, J Lindesay, ... International journal of geriatric psychiatry 26 (8), 812-817, 2011 | 176 | 2011 |
| Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals S Rehal, TP Morris, K Fielding, JR Carpenter, PPJ Phillips BMJ open 6 (10), e012594, 2016 | 160 | 2016 |
| Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment I Honeyborne, TD McHugh, PPJ Phillips, S Bannoo, A Bateson, N Carroll, ... Journal of clinical microbiology 49 (11), 3905-3911, 2011 | 145 | 2011 |
| Timing of relapse in short-course chemotherapy trials for tuberculosis AJ Nunn, PPJ Phillips, DA Mitchison The International journal of tuberculosis and lung disease 14 (2), 241-242, 2010 | 138 | 2010 |
| Short intensified treatment in children with drug-susceptible tuberculous meningitis R van Toorn, HS Schaaf, JA Laubscher, SL van Elsland, PR Donald, ... The Pediatric infectious disease journal 33 (3), 248-252, 2014 | 136 | 2014 |
| Radiological cavitation, sputum mycobacterial load and treatment response in pulmonary tuberculosis FMR Perrin, N Woodward, PPJ Phillips, TD McHugh, AJ Nunn, ... The International journal of tuberculosis and lung disease 14 (12), 1596-1602, 2010 | 119 | 2010 |
| Biomarkers for tuberculosis disease activity, cure, and relapse PPJ Phillips, GR Davies, DA Mitchison The Lancet infectious diseases 10 (2), 69-70, 2010 | 116 | 2010 |
| Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis F Fregonese, SD Ahuja, OW Akkerman, D Arakaki-Sanchez, I Ayakaka, ... The lancet respiratory medicine 6 (4), 265-275, 2018 | 111 | 2018 |
| An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse PPJ Phillips, K Fielding, AJ Nunn PloS one 8 (5), e63840, 2013 | 106 | 2013 |
Stephen H. GillespieUniversity of St AndrewsVerified email at st-andrews.ac.uk